Endometrium Kanseri ve Hemşirelik Bakımı
Özet
Endometriyum kanseri, uterusun iç tabakasındaki epitelyum kısmında gelişen ve gelişmiş ülkelerde en sık görülen jinekolojik kanser türüdür. Histolojik ve klinik özelliklerine göre Tip I (%80-90) ve Tip II (%10-20) olmak üzere iki gruba ayrılır; Tip I daha genç yaşlarda görülüp iyi prognoza sahipken, Tip II ileri yaşlarda ortaya çıkar ve agresif seyreder. En önemli risk faktörleri arasında obezite, diyabet, hipertansiyon, aile öyküsü (Lynch sendromu), tamoksifen kullanımı ve karşılanmamış östrojen maruziyeti yer alır. Hastalığın en yaygın belirtisi anormal uterin kanamalardır ve kesin tanı histopatolojik incelemeyle konur. Tedavi planlaması kanserin evresine göre cerrahi (genellikle TAH+BSO), kemoterapi, radyoterapi, hormonal tedavi veya yeni terapötik yaklaşımları içerir. Kanser kontrolünün dört basamağını oluşturan önleme, tarama, yönetim ve palyatif bakım süreçlerinde birincil, ikincil ve üçüncül korunma stratejileri uygulanır. Bu süreçte hemşireler; semptom yönetimi, hastaların fizyolojik/psikolojik iyilik halinin sürdürülmesi, cinsel danışmanlık, sağlıklı yaşam tarzı eğitimi ve bakım verici/eğitici rolleriyle hayati ve kilit bir sorumluluğa sahiptir.
Endometrial cancer develops in the epithelial part of the inner layer of the uterus and is the most common gynecological cancer type in developed countries. It is divided into two groups as Type I (80-90%) and Type II (10-20%) based on its histological and clinical features; while Type I is seen at younger ages and has a favorable prognosis, Type II occurs at older ages and follows an aggressive course. Its most significant risk factors include obesity, diabetes, hypertension, family history (Lynch syndrome), tamoxifen use, and un-opposed estrogen exposure. The most common symptom of the disease is abnormal uterine bleeding, and the definitive diagnosis is established through histopathological examination. Treatment planning involves surgery (usually TAH+BSO), chemotherapy, radiotherapy, hormonal therapy, or novel therapeutic approaches depending on the stage of the cancer. Primary, secondary, and tertiary prevention strategies are implemented within the four stages of cancer control, which consist of prevention, screening, management, and palliative care. Throughout this process, nurses hold a vital and pivotal responsibility through symptom management, maintaining patients' physiological and psychological well-being, sexual counseling, healthy lifestyle education, and their caregiving and educational roles.
Referanslar
Sun H, Chang Q, Liu YS, et al. Adherence to cancer prevention guidelines and endometrial cancer risk:evidence from a systematic review and dose-response meta-analysis of prospective studies. Cancer Res Treat, 2021;53(1):223-232. DOI: https://doi.org/10.4143/crt.2020.546
Cancer Statistics Center (2020). Cancer Statistics. (04/05/2021 tarihinde http://cancerstatisticscenter.cancer.org adresinden ulaşılmıştır).
T.C. Sağlık Bakanlığı (2019). Türkiye Kanser İstatistikleri 2016. (04/05/2021 tarihinde https://hsgm.saglik.gov.tr/tr/kanser-istatistikleri adresinden ulaşılmıştır).
Abu-Rustum NR, Yashar CM, Bean S, et al. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. J Natl Compr Canc Netw, 2020;18(6):660-666. DOI:10.6004/jnccn.2020.0027
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. NCCN guidelines ınsights: ovarian cancer, version 1.2019. J Natl Compr Canc Netw, 2019;17(8):896-909. doi:10.6004/jnccn.2019.0039
Siegel RL, Miller DK, Jemal A. Cancer Statistics. CA: A Cancer Journal For Clinicians, 2017; 67(1):7-30.
Heerik AS, Horeweg N, Boer SM, et al. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. Int J Gynecol Cancer, 2020;0:1-11. DOI:10.1136/ijgc-2020-001822
Bilge Ç, Kaydırak MM, Aslan E. Jinekolojik kanserin cinsel yaşam üzerindeki etkileri. SDÜ Sağlık Bilimleri Enstitüsü Dergisi, 2016;7:31-38.
Körükcü Ö. Bazı yaşamsal geçişler zordur jinekolojik kanser tanısı almak gibi... ACU Sağlık Bil Derg, 2018;9(3):248-254.
Aslan K, Yalçın İ, Şahin H, et al. LVSI pozitif ve grade 1-2 tümörü olan evre IA ve evre IB endometrial kanser hastalarının karşılaştırılması: 2016 yılında ESMO-ESGO-ESTRO tarafından tanımlanmış olan yüksek-orta risk grubunun analizi. Zeynep Kamil Tıp Bülteni, 2019;50(3):112-116. DOI:10.16948/zktipb.585846
Falcone F, Laurelli G, Losito S, et al. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol, 2017;28(1):2-8.
Koh WJ, Abu-Rustum NR, Bean S, et al. Uterine Neoplasms, Version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2018;16(2):170-199. DOI:10.6004/jnccn.2018.0006.
Passarello K, Kurian S, Villanueva V. Endometrial Cancer: An overview of pathophysiology, management, and care. Semin Oncol Nurs, 2019;35(2):157-165. DOI:10.1016/j.soncn.2019.02.002.
Amant F, Mirza MR, Koskas M, et al. Cancer of the corpus uteri. Int J Gynaecol Obstet, 2018;143(2):37-50. DOI:10.1002/ijgo.12612.
Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Radiotherapy and Oncology, 2021;154:327–353. DOI: https://doi.org/10.1016/j.radonc.2020.11.018
Wise M, Jordan V, Lagas A, et al. Obesity and endometrial hyperplasia and cancer ın premenopausal women: A systematic review. Am J Obstet Gynecol, 2016;214(6):689-695.
Win AK, Reece JC, Ryan S. Family history and risk of endometrial cancer: a systematic review and meta-analysis. Obstetrics & Gynecology, 2015;125(1):89-98.
Hsu HT, Lin KC, Wu LM, et al. Symptom cluster trajectories during chemotherapy in breast cancer outpatients. J Pain Symptom Manage, 2017;53(6):1017-1025. DOI:10.1016/j.jpainsymman.2016.12.354.
Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: A systematic review. Cancer Epidemiol Biomarkers Prev, 2013;22(11):1931-1943.
Gökçü M, Erkılınç S, Solmaz U, vd. Yüksek riskli ve düşük riskli endometrium kanserleri hastalarda ileri yaş kötü prognostik bir faktör müdür? Bozok Tıp Dergisi, 2018;8(3):99-108.
Vanderstraeten A, Tuyaerts S, Amant F. The immune system in the normal endometrium and implications for endometrial cancer development. Journal of Reproductive Immunology, 2015;109:7-16. DOI: 10.1016/j.jri.2014.12.006.
Raphaelis S, Kobleder A, Mayyer H, et al. Effectiveness, structure, and content of nurse counseling in gynecologic oncology: A systematic review. BMC Nursing, 2017;16(43):2-17. DOI: 10.1186/s12912-017-0237-z.
Barsevick A. Defining the Symptom Cluster: How Far Have We Come? Semin Oncol Nurs, 2016;32(4):334-350. doi:10.1016/j.soncn.2016.08.001
Del Carmen MG, Rice LW. Management of menopausal symptoms in women with gynecologic cancers. Gynecol Oncol, 2017;146(2):427-435. DOI:10.1016/j.ygyno.2017.06.013.
Sert F, Alanyalı S, Aras AB, vd. Evre I endometrium kanserinde uygulanan radyoterapi şeklinin uzun dönem yan etki sonuçlarına etkisi: pelvik eksternal radyoterapi veya vaginal brakiterapi? Türk Jinekolojik Onkoloji Dergisi. 2016;4:145-150.
Aksu G. Serviks ve endometrium kanserinde brakiterapi. Turk J Oncol, 2017;32:34-45.
Gupta S, Provenzale D, Regenbogen SE, et al. NCCN guidelines insights: genetic/ familial high-risk assessment: colorectal. Version 3.2017. J Natl Compr Canc Netw, 2017;15:1465-1475.
Hubbs JL, Saig RM, Abaid LN, et al. Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma. Obstet Gynecol, 2013;121:1172-1180.
Tran AQ, Gehrig P. Recent advances in endometrial cancer. F1000Res, 2017;6:81-85.
Morice P, Leary A, Creutzberg C, et al. Endometrial cancer. Lancet. 2016;387:1094-1108.
Bradford LS, Rauh-Hain JA, Schorge J, et al. Advances in the management of recurrent endometrial cancer. Am J Clin Oncol, 2015;38:206-212.
Thompson DJ, O’Mara TA, Glubb DM, et al. CYP19A1 fine-mapping and Mendelian randomization: Estradiol is causal for endometrial cancer. Endocr. Relat. Cancer, 2016;23:77-91.
Schultheis AM, Martelotto LG, De Filippo MR, et al. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers. Int. J. Gynecol. Pathol, 2016;35:289-300.
Edmondson R, Crosbie E, Nickkho-Amiry M., et al. Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A Trans PORTEC initiative. Gynecol. Oncol, 2017;146:327-333.
Obata T, Nakamura M., Mizumoto Y, et al. Dual expression of immunoreactive estrogen receptor β and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma. PLoS ONE, 2017;12:e0188641.
Nakamura M, Obata T, Daikoku T, et al. The association and significance of p53 in gynecologic cancers: the potential of targeted therapy. Int. J. Mol. Sci, 2019;20:5482. DOI:10.3390/ijms20215482.
Ferlay J, Isabelle S, Dikshit R, et al. Cancer incidence and mortality wolrdwide: Sources, methods and major patterns in GLOBACON 2012. Internal Journal of Cancer, 2015;136:E359-86.
Dikmen HA, Terzioğlu F. Effects of reflexology and progressive muscle relaxation on pain, fatigue and quality of life during chemotherapy in gynecologic cancer patients. Pain Manag Nurs, 2018;15:1-10.
Chase DM, Gibson SJ, Summer DA, et al. Appropriate use of complementary and alternative medicine approaches in gynecologic cancers. Curr Treat Options Oncol. 2014;15(1):14-26.
Başgöl Ş, Aslan E. Jinekolojik kanserlerin tedavisinde tamamlayıcı ve alternatif tedavi: Kanıta dayalı yaklaşım. YBÜ Sağlık Bilimleri Fakültesi Hemşirelik E-Dergisi, 2014;2(3):51- 62.
Ben-Arye E, Samuels N, Goldstein LH, et al. Potential risks associated with traditional herbal medicine use in cancer care: a study of middle eastern oncology health care professionals. Cancer. 2016;122(4):598- 610.
Peksoy S, Demirhan İ, Kaplan S, vd. Tamamlayıcı ve alternatif tedavinin jinekolojik kanserlerde kullanımı. Türkiye Sağlık Bilimleri ve Araştırmaları Dergisi, 2018;1(1):36-47.
Eroğlu K, Koç G. Jinekolojik kanser kontrolü ve hemşirelik. Hacettepe Üniversitesi Hemşirelik Fakültesi Dergisi, 2014;1(2):77-90.
Moore K, Brewer MA. Endometrial cancer: Is this a new disease? Am Soc Clin Oncol Educ Book, 2017;37:435-442. DOI: 10.1200/EDBK_175666.
MacKintosh ML, Crosbie EJ. Prevention strategies in endometrial carcinoma. Current Oncology Reports, 2018;20:101-108.
Ward KK, Roncancio AM, Shah NR, et al. Bariatric surgery decreases the risk of uterine malignancy. Gynecol Oncol, 2014;133(1):63-66.
Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Lond Engl, 2011;378(9809): 2081-2087.
Beavis AL, Smith AJB, Fader AN. Lifestyle changes and the risk of developing endometrial and ovarian cancers: opportunities for prevention and management. Int J Womens Health, 2016;8:151-167.
Wu SF, Tong HY, Kan YY, et al. The exploration of health-related quality of life: Factors influencing quality of life in gynecologic cancer patients. Clin Nurs Res, 2017;26(1):114-131. DOI:10.1177/1054773815600665
Beck SL, Eaton LH, Echeverria C, et al. SymptomCare@Home: Developing an ıntegrated symptom monitoring and management system for outpatients receiving chemotherapy. Comput Inform Nurs, 2017;35(10):520-529. DOI:10.1097/CIN.0000000000000364.
Makker V, Green AK, Wenham RM, et al. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecologic Oncology Research and Practice, 2017;4(19):2-12. DOI: 10.1186/s40661-017-0056-7
Goulet D, Danilack V, Matteson KA. Enhanced recovery pathways for improving outcomes after minimally invasive gynecologic oncology surgery. Obstetrics ve Gynecology, 2017;129(1):207-208.
